CDK6 and nasopharyngeal carcinoma: To the best of our knowledge, miR‐892b can mediate the progression of cancers via regulating the expression of pathways such as NF‐κB (breast cancer),25 p19ARF/cyclin D1/CDK6 and Sp‐1/MMP‐9 (bladder cancer).24 However, how miR‐892b exerts its inhibitory effects on NPC remains unknown.